Futura Medical

Fund raise of £2.25m, at 8p a share, confirmed at EGM

Lighthouse | 21 January 2020

Share this note

  • In late December Futura Medical raised a total of £3.25m (gross of expenses) through the issue of 40.6m shares at 8p a share. £1.5m of the raise was carried out through PrimaryBid, a platform open to retail investors. A further £1.75m was subscribed for directly by Lombard Odier. The new shares represent circa 16.66% of the enlarged share capital.
  • The funds will be used for working capital purposes, including the closing out costs for the pivotal FM57 study, and to pursue a medical devices pathway for the regulatory approvals of DermaSys gel in the treatment of erectile dysfunction (ED).
  • This follows publication of the top-line results of the FM57 Phase III trial for MED2005, an erectogenic gel containing glyceryl trinitrate (GTN). The study showed MED2005 met the primary endpoints against baseline and, rather surprisingly, also demonstrated a significant clinical benefit for DermaSys gel alone. However, as a consequence, there was no statistical difference between MED2005 and the placebo arm.
  • Management is exploring the regulatory pathways for the DermaSys gel alone to be approved for the treatment of ED. It believes no further significant clinical work will be required for European approval as a medical device. The situation in the US is expected to be similar but cannot be confirmed until a meeting with the FDA has happened (likely during Q120).
  • The fund raise, along with existing cash resources, means that Futura Medical has sufficient working capital for at least 12 months on current plans. This is based on assuming that approval of the DermaSys formulation for treating ED would not require material additional clinical studies to be performed.

Trinity Delta view: The fund raise extends Futura Medical’s cash runway, on current plans, through to end-2020. We suspended our forecasts and valuation when the FM57 study results were announced. As we said at the time, these remarkable results have created understandable uncertainty and until we have greater visibility that is the prudent action to take. There are clear opportunities for DermaSys being approved as a treatment for ED, including the extended patent life and wider market opportunities; however, there are potential unknowns that remain. The planned meeting with the FDA will shed further light on the next steps. We intend to reinstate our forecasts as soon as practicable.


21 January 2020

Market Cap£31.3m
Primary exchangeAIM
Company CodeFUM
Corporate clientYes

Company description

Futura Medical is an R&D driven small pharma company, with a novel DermaSys transdermal delivery platform. The lead programme, a topically applied gel, is being developed for erectile dysfunction (ED). A pain relief gel, TPR100, is awaiting UK approval.


Lala Gregorek
+44 (0) 20 3637 5043

Franc Gregori
+44 (0) 20 3637 5041


Trinity Delta Research Limited (“TDRL”; firm reference number: 725161), which trades as Trinity Delta, is an appointed representative of Equity Development Limited (“ED”). The contents of this report, which has been prepared by and is the sole responsibility of TDRL, have been reviewed, but not independently verified, by ED which is authorised and regulated by the FCA, and whose reference number is 185325.

ED is acting for TDRL and not for any other person and will not be responsible for providing the protections provided to clients of TDRL nor for advising any other person in connection with the contents of this report and, except to the extent required by applicable law, including the rules of the FCA, owes no duty of care to any other such person. No reliance may be placed on ED for advice or recommendations with respect to the contents of this report and, to the extent it may do so under applicable law, ED makes no representation or warranty to the persons reading this report with regards to the information contained in it.

In the preparation of this report TDRL has used publically available sources and taken reasonable efforts to ensure that the facts stated herein are clear, fair and not misleading, but make no guarantee or warranty as to the accuracy or completeness of the information or opinions contained herein, nor to provide updates should fresh information become available or opinions change.

Any person who is not a relevant person under section of Section 21(2) of the Financial Services & Markets Act 2000 of the United Kingdom should not act or rely on this document or any of its contents. Research on its client companies produced by TDRL is normally commissioned and paid for by those companies themselves (‘issuer financed research’) and as such is not deemed to be independent, as defined by the FCA, but is ‘objective’ in that the authors are stating their own opinions. The report should be considered a marketing communication for purposes of the FCA rules. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and it is not subject to any prohibition on dealing ahead of the dissemination of investment research. TDRL does not hold any positions in any of the companies mentioned in the report, although directors, employees or consultants of TDRL may hold positions in the companies mentioned. TDRL does impose restrictions on personal dealings. TDRL might also provide services to companies mentioned or solicit business from them.

This report is being provided to relevant persons to provide background information about the subject matter of the note. This document does not constitute, nor form part of, and should not be construed as, any offer for sale or purchase of (or solicitation of, or invitation to make any offer to buy or sell) any Securities (which may rise and fall in value). Nor shall it, or any part of it, form the basis of, or be relied on in connection with, any contract or commitment whatsoever. The information that we provide is not intended to be, and should not in any manner whatsoever be, construed as personalised advice. Self-certification by investors can be completed free of charge at www.fisma.org. TDRL, its affiliates, officers, directors and employees, and ED will not be liable for any loss or damage arising from any use of this document, to the maximum extent that the law permits.

Copyright 2020 Trinity Delta Research Limited. All rights reserved.